Jan 13 (Reuters) – The U.S. Food and Drug Administration on Tuesday requested companies to remove warnings related to the potential risk of suicidal ideation from the labeling of popular weight-loss drugs of the GLP-1 class.
The action follows a comprehensive FDA review that found no increased risk of suicidal ideation and behavior associated with the use of GLP-1 drugs, which include Novo Nordisk’s Wegovy and older drug Saxenda, and Eli Lilly’s Zepbound.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Comments